IN2014DN11063A - - Google Patents
Info
- Publication number
- IN2014DN11063A IN2014DN11063A IN11063DEN2014A IN2014DN11063A IN 2014DN11063 A IN2014DN11063 A IN 2014DN11063A IN 11063DEN2014 A IN11063DEN2014 A IN 11063DEN2014A IN 2014DN11063 A IN2014DN11063 A IN 2014DN11063A
- Authority
- IN
- India
- Prior art keywords
- polyester
- polyethylene glycol
- copolymer containing
- active principle
- bupivacaine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665192P | 2012-06-27 | 2012-06-27 | |
| PCT/IB2013/001547 WO2014001904A1 (en) | 2012-06-27 | 2013-06-27 | Biodegradable drug delivery for hydrophobic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN11063A true IN2014DN11063A (hu) | 2015-09-25 |
Family
ID=49117888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN11063DEN2014 IN2014DN11063A (hu) | 2012-06-27 | 2013-06-27 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20150150987A1 (hu) |
| EP (1) | EP2866837B1 (hu) |
| JP (1) | JP6134788B2 (hu) |
| KR (1) | KR102189442B1 (hu) |
| CN (1) | CN104582733B (hu) |
| AU (1) | AU2013282891B2 (hu) |
| BR (1) | BR112014031773B1 (hu) |
| CA (1) | CA2877083C (hu) |
| CL (1) | CL2014003531A1 (hu) |
| CO (1) | CO7160098A2 (hu) |
| CR (1) | CR20140581A (hu) |
| CU (1) | CU24287B1 (hu) |
| EA (1) | EA031522B1 (hu) |
| ES (1) | ES2938586T3 (hu) |
| HK (1) | HK1208374A1 (hu) |
| IL (1) | IL236472B (hu) |
| IN (1) | IN2014DN11063A (hu) |
| MA (1) | MA37809B1 (hu) |
| MX (1) | MX353280B (hu) |
| SG (1) | SG11201408658PA (hu) |
| TN (1) | TN2014000520A1 (hu) |
| UA (1) | UA113549C2 (hu) |
| WO (2) | WO2014001904A1 (hu) |
| ZA (1) | ZA201409291B (hu) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10251937B2 (en) | 2014-01-27 | 2019-04-09 | Medincell | Retro-inverso analogs of spadin display increased antidepressant effects |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CN107072948A (zh) * | 2014-09-30 | 2017-08-18 | 田纳西大学研究基金会 | 用于长效药物传递的原位凝胶剂 |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| FR3027522B1 (fr) | 2014-10-27 | 2016-12-09 | I Ceram | Composition poreuse chargee en principe actif |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| FI3377041T3 (fi) | 2015-11-16 | 2023-11-30 | Medincell S A | Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2018081138A1 (en) * | 2016-10-24 | 2018-05-03 | Yale University | Biodegradable contraceptive implants |
| AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| BR112020001031A2 (pt) | 2017-07-17 | 2020-07-14 | Medincell | misturas de composições de liberação de fármaco biodegradáveis para modular a cinética de liberação de fármaco de pelo menos um ingrediente ativo |
| CN108078911A (zh) * | 2017-12-08 | 2018-05-29 | 复旦大学 | 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法 |
| AU2019325261A1 (en) * | 2018-08-22 | 2021-03-18 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
| GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| EP4027973A1 (en) | 2019-09-13 | 2022-07-20 | Medincell SA | Drug delivery formulations |
| CN111700876A (zh) * | 2020-03-12 | 2020-09-25 | 上海市肿瘤研究所 | 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法 |
| US20240099964A1 (en) | 2020-12-16 | 2024-03-28 | Medincell S.A. | Methods and Compositions for the Prophylactic Treatment of SARS-CoV-2 virus (COVID-19) |
| FI20215186A1 (en) | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
| CA3208006A1 (en) | 2021-03-17 | 2022-09-22 | Avia MERENLENDER WAGNER | Long acting injectable formulation comprising risperidone and biodegradable polymers |
| CA3217538A1 (en) * | 2021-04-30 | 2022-11-03 | Medincell Sa | New formulation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| CN100408099C (zh) * | 2000-11-09 | 2008-08-06 | 阿斯特拉曾尼卡有限公司 | 含有嵌段共聚物的口服药物组合物 |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| DE60220519T2 (de) | 2001-04-20 | 2007-09-27 | The University Of British Columbia, Vancouver | Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe |
| US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| DE602004007802T2 (de) * | 2003-06-26 | 2008-04-17 | Mediolanum Pharmaceuticals Ltd. | Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung |
| US20050112170A1 (en) | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
| CA2618404A1 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| CN101273963A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 一种含激素类抗癌药的温控缓释注射剂 |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| KR20110091515A (ko) * | 2008-11-21 | 2011-08-11 | 주식회사 삼양사 | 내성암 치료용 고분자 미셀 조성물 및 그 제조방법 |
| CN101810560B (zh) * | 2009-02-20 | 2013-07-10 | 北京大学 | 环孢a聚合物胶束组合物 |
| EP3586825B1 (en) * | 2010-12-29 | 2023-01-18 | Medincell S.A. | Biodegradable drug delivery compositions |
-
2013
- 2013-06-27 MX MX2014015902A patent/MX353280B/es active IP Right Grant
- 2013-06-27 KR KR1020157002309A patent/KR102189442B1/ko active IP Right Grant
- 2013-06-27 WO PCT/IB2013/001547 patent/WO2014001904A1/en active Application Filing
- 2013-06-27 US US14/410,994 patent/US20150150987A1/en not_active Abandoned
- 2013-06-27 UA UAA201413827A patent/UA113549C2/uk unknown
- 2013-06-27 SG SG11201408658PA patent/SG11201408658PA/en unknown
- 2013-06-27 JP JP2015519379A patent/JP6134788B2/ja active Active
- 2013-06-27 WO PCT/IB2013/001549 patent/WO2014001905A1/en active Application Filing
- 2013-06-27 ES ES13758976T patent/ES2938586T3/es active Active
- 2013-06-27 MA MA37809A patent/MA37809B1/fr unknown
- 2013-06-27 CN CN201380044335.7A patent/CN104582733B/zh active Active
- 2013-06-27 AU AU2013282891A patent/AU2013282891B2/en active Active
- 2013-06-27 IN IN11063DEN2014 patent/IN2014DN11063A/en unknown
- 2013-06-27 CU CUP2014000148A patent/CU24287B1/xx unknown
- 2013-06-27 CA CA2877083A patent/CA2877083C/en active Active
- 2013-06-27 BR BR112014031773-9A patent/BR112014031773B1/pt active IP Right Grant
- 2013-06-27 EA EA201492172A patent/EA031522B1/ru not_active IP Right Cessation
- 2013-06-27 EP EP13758976.8A patent/EP2866837B1/en active Active
-
2014
- 2014-12-15 TN TN2014000520A patent/TN2014000520A1/fr unknown
- 2014-12-16 CR CR20140581A patent/CR20140581A/es unknown
- 2014-12-17 ZA ZA2014/09291A patent/ZA201409291B/en unknown
- 2014-12-24 CL CL2014003531A patent/CL2014003531A1/es unknown
- 2014-12-25 IL IL236472A patent/IL236472B/en active IP Right Grant
- 2014-12-26 CO CO14284191A patent/CO7160098A2/es unknown
-
2015
- 2015-09-18 HK HK15109165.3A patent/HK1208374A1/xx unknown
-
2018
- 2018-07-30 US US16/049,580 patent/US20190160171A1/en not_active Abandoned
-
2019
- 2019-11-22 US US16/692,487 patent/US20200085958A1/en not_active Abandoned
-
2020
- 2020-09-18 US US17/025,826 patent/US20210008216A1/en not_active Abandoned
-
2022
- 2022-05-19 US US17/748,464 patent/US20220354956A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN11063A (hu) | ||
| TN2013000267A1 (en) | Biodegradable drug delivery compositions | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| WO2012075362A3 (en) | Chemokine cxcr4 receptor modulators and used related thereto | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| WO2011101863A3 (en) | Extended release pharmaceutical compositions of lacosamide | |
| IN2013MU03658A (hu) | ||
| MD20150053A2 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
| WO2012064302A3 (en) | Improved montelukast formulations | |
| WO2012029074A3 (en) | Pharmaceutical compositions of linezolid | |
| TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
| WO2011039675A3 (en) | Latrepirdine transdermal therapeutic dosage forms | |
| WO2013112806A3 (en) | Transdermal hormone delivery | |
| TN2011000352A1 (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
| UA97076C2 (ru) | Мазь противовоспалительная на основе сульфаниламида | |
| LT2009004A (en) | New combination of active ingredients containing a non steroidal antiimplamatotory drug and a colchicoside derivative |